The markets opened lower with the Dow dropping 56 points to 17,928 as Greece met with its European creditors. Nasdaq lost 7 points to 4,917.

On the upside

The Food and Drug Administration accepted Celsion's (Nasdaq: CLSN) planned Phase 1 dose-escalation clinical trial of the DNA-based immunotherapy GEN-1.

California Resources (NYSE: CRC) fell to a loss for the fourth quarter but the company reported record quarterly production.

Fourth quarter earnings and revenue surged for Arista Networks (NYSE: ANET) to beat analyst expectations.

On the downside

CollabRx (Nasdaq: CLRX) priced its public offering of 3.84 million common shares at the discounted price of $1.25 per share.

Noodles & Co. (Nasdaq: NDLS) reported higher fourth quarter earnings and revenue but the results fell short of analyst expectations.

Rocket Fuel (Nasdaq: FUEL) widened losses for the fourth quarter despite higher revenue as expenses soared.

In the broad market, declining issues outpaced advancers by a margin of more than 7 to 5 on the NYSE and by more than 5 to 3 on Nasdaq. The broader S&P 500 lost 7 points to 2089. Bitcoin added $3 to $242.